DCVax: Slowing the Progression of Metastatic Prostate Cancer.

Prostate cancer patients whom experience rising PSA levels while on hormone treatment typically progress to metastatic disease on average in about 28-36 weeks. DCVax is a vaccine made from a patient’s own dendritic cells and loaded with a form of the Prostate Specific Membrane Antigen. In this study of patients taking DCVax, none had progressed to metastatic disease at 28 weeks and only half have progressed at 59 weeks.
I like this approach because it not only does it provides treatment options for metastatic and castration resistant prostate cancer, but it does so with minimal side effects.
Updates For DCVax


Comments

  1. Great delivery. Great arguments. Keep up
    the amazing effort.

Speak Your Mind

*